Oseltamivir analogs with potent anti-influenza virus activity

Kumar, Sumit; Goicoechea, Steven; Kumar, Sonu; Pearce, Catherine M.; Durvasula, Ravi; Kempaiah, Prakasha; Rathi, Brijesh; Poonam, .

doi:10.1016/j.drudis.2020.06.004

Cited by 21 publications

(12 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These AEs usually accompany the first dose of the drug and disappear within the first 2 days of therapy. To alleviate these symptoms, it is recommended to take the drugs in the form of tablets or capsules with food [ 54 , 132 ]. The exception is zanamivir for inhalation (Relenza ® ), which is most often associated with disorders of the respiratory system [ 64 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Antiviral Drugs in Influenza

Świerczyńska

Mirowska‐Guzel

Pindelska

2022

IJERPH

View full text Add to dashboard Cite

Flu is a serious health, medical, and economic problem, but no therapy is yet available that has satisfactory results and reduces the occurrence of these problems. Nearly 20 years after the registration of the previous therapy, baloxavir marboxil, a drug with a new mechanism of action, recently appeared on the market. This is a promising step in the fight against the influenza virus. This article presents the possibilities of using all available antiviral drugs specific for influenza A and B. We compare all currently recommended anti-influenza medications, considering their mechanisms of action, administration, indications, target groups, effectiveness, and safety profiles. We demonstrate that baloxavir marboxil presents a similar safety and efficacy profile to those of drugs already used in the treatment of influenza. Further research on combination therapy is highly recommended and may have promising results.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Despite the significant efficiency of all NAIs, there is a constant need to improve and synthesize new variants due to the rapid, spontaneous, and uncontrolled variability in the influenza virus and the emerging drug resistance of some new strains [ 47 , 54 ].…”

Section: Drugs Used For Influenza Treatment and Prophylaxismentioning

confidence: 99%

Antiviral Drugs in Influenza

Świerczyńska

Mirowska‐Guzel

Pindelska

2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…The segmented genome of influenza viruses provides an advantage for viral evolution, and the exchange of viral genome segments (or antigenic transfer) between different strains of the same type of virus, or the introduction of mutations in the genome (antigenic drift), can lead to viral mutants that are resistant to current antiviral drugs or neutralizing antibodies (NAbs). 14 Three classes of drugs are currently FDA-approved and registered specifically for influenza viruses [15][16][17][18] : neuraminidase inhibitors (zanamivir, oseltamivir, and paramivir), which prevent viral release; cap-dependent nucleic acid endonuclease inhibitors (baloxavir), which prevent viral replication. M2 ion channel inhibitors (amantadine, amantadine) inhibit the first stages of the viral life cycle.…”

Section: Introductionmentioning

confidence: 99%

Influenza virus cell entry and targeted antiviral development

Zhu,

Anirudhan,

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Influenza virus infection is currently one of the most prevalent and transmissible diseases in the world causing local outbreaks every year. It has the potential to cause devastating global pandemics as well. The development of anti‐influenza drugs possessing novel mechanisms of action is urgently needed to control the spread of influenza infections; thus, drugs that inhibit influenza virus entry into target cells are emerging as a hot research topic. In addition to discussing the biological significance of hemagglutinin in viral replication, this article provides recent updates on the natural products, small molecules, proteins, peptides, and neutralizing antibody‐like proteins that have anti‐influenza potency.

show abstract

“…Despite significant progress in the search for drugs that can suppress the replication of the influenza virus at different stages of reproduction, only three groups of drugs are used in healthcare. The three categories of anti-influenza drugs are as follows: the neuraminidase (NA) inhibitors such as oseltamivir (Tamiflu) − and zanamivir that have been approved in many countries worldwide, peramivir − and laninamivir − are approved in Japan. Peramivir is also approved in China and the Republic of Korea .…”

Section: Introductionmentioning

confidence: 99%

Naturally Occurring Isorhamnetin Glycosides as Potential Agents Against Influenza Viruses: Antiviral and Molecular Docking Studies

Bogoyavlenskiy,

Zaitseva,

Alexyuk

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Influenza remains one of the most widespread infections, causing an annual illness in adults and children. Therefore, the search for new antiviral drugs is one of the priorities of practical health care. Eight isorhamnetin glycosides were purified from Persicaria species, characterized by nuclear magnetic resonance spectroscopy and mass spectrometry and then evaluated as potential agents against influenza virus. A comprehensive in vitro and in vivo assessment of the compounds revealed that compound 5 displayed the most potent inhibitory activity with an EC 50 value of 1.2–1.3 μM, better than standard drugs (isorhamnetin 28.0–56.0 μM and oseltamivir 1.3–9.1 μM). Molecular docking results also revealed that compound 5 has the lowest binding energy (−10.7 kcal/mol) among the tested compounds and isorhamnetin (−8.1 kcal/mol). The ability of the isorhamnetin glycosides to suppress the reproduction of the influenza virus was studied on a model of a cell culture and chicken embryos. The ability of active compounds to influence the structure of the virion, as well as the activity of hemagglutinin and neuraminidase, has been demonstrated. Compound 1, 5, and 6 demonstrated the most effective inhibition of virus replication for all tested viruses. Molecular dynamics simulation techniques were run for 100 ns for compound 5 with two protein receptors Hem (1RUY) and Neu (3BEQ). These results revealed that the Hem-complex system acquired a relatively more stable conformation and even better descriptors than the other Neu-complex studied systems, suggesting that it can be an effective inhibiting drug toward hemagglutinin than neuraminidase inhibition. Based on the reported results, compound 5 can be a good candidate to be evaluated for effectiveness in preclinical testing.

show abstract

Oseltamivir analogs with potent anti-influenza virus activity

Cited by 21 publications

References 75 publications

Antiviral Drugs in Influenza

Antiviral Drugs in Influenza

Influenza virus cell entry and targeted antiviral development

Naturally Occurring Isorhamnetin Glycosides as Potential Agents Against Influenza Viruses: Antiviral and Molecular Docking Studies

Contact Info

Product

Resources

About